Glucorticoid Taper Regimen ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 40 | Takayasu arteritis | 2 |
40. Takayasu arteritis
Clinical trials : 24 / Drugs : 40 - (DrugBank : 18) / Drug target genes : 23 - Drug target pathways : 110
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCT2061210007 | 13/10/2021 | 28/05/2021 | A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK) | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Takayasu Arteritis | Takayasu Arteritis | Ustekinumab Participants will receive IV infusion and SC injection of ustekinumab. Placebo Participants will receive IV infusion and SC injection of matching placebo. Glucorticoid Taper Regimen Glucocorticoid will be administered orally. | Nishikawa Kazuko | NULL | Recruiting | >= 18age old | <= 75age old | Both | 50 | Phase 3 | Japan |
| 2 | NCT04882072 (ClinicalTrials.gov) | September 15, 2021 | 10/5/2021 | A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK) | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Takayasu Arteritis | Takayasu Arteritis | Drug: Ustekinumab;Other: Placebo;Drug: Glucorticoid Taper Regimen | Janssen Pharmaceutical K.K. | NULL | Active, not recruiting | 15 Years | 75 Years | All | 14 | Phase 3 | Japan |